These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

641 related items for PubMed ID: 22928703

  • 1. Single application of high-intensity focused ultrasound as a first-line therapy for clinically localized prostate cancer: 5-year outcomes.
    Pfeiffer D, Berger J, Gross AJ.
    BJU Int; 2012 Dec; 110(11):1702-7. PubMed ID: 22928703
    [Abstract] [Full Text] [Related]

  • 2. Single-session primary high-intensity focused ultrasonography treatment for localized prostate cancer: biochemical outcomes using third generation-based technology.
    Pinthus JH, Farrokhyar F, Hassouna MM, Woods E, Whelan K, Shayegan B, Orovan WL.
    BJU Int; 2012 Oct; 110(8):1142-8. PubMed ID: 22372721
    [Abstract] [Full Text] [Related]

  • 3. Evolution and outcomes of 3 MHz high intensity focused ultrasound therapy for localized prostate cancer during 15 years.
    Thüroff S, Chaussy C.
    J Urol; 2013 Aug; 190(2):702-10. PubMed ID: 23415962
    [Abstract] [Full Text] [Related]

  • 4. HIFU as salvage first-line treatment for palpable, TRUS-evidenced, biopsy-proven locally recurrent prostate cancer after radical prostatectomy: a pilot study.
    Asimakopoulos AD, Miano R, Virgili G, Vespasiani G, Finazzi Agrò E.
    Urol Oncol; 2012 Sep; 30(5):577-83. PubMed ID: 21292508
    [Abstract] [Full Text] [Related]

  • 5. Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients.
    Crouzet S, Chapelon JY, Rouvière O, Mege-Lechevallier F, Colombel M, Tonoli-Catez H, Martin X, Gelet A.
    Eur Urol; 2014 May; 65(5):907-14. PubMed ID: 23669165
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Experience with high-intensity focused ultrasound therapy for management of organ-confined prostate cancer: critical evaluation of oncologic outcomes.
    Komura K, Inamoto T, Masuda H, Watsuji T, Azuma H.
    Acta Biomed; 2012 Dec; 83(3):189-96. PubMed ID: 23762994
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Location of residual cancer after transrectal high-intensity focused ultrasound ablation for clinically localized prostate cancer.
    Boutier R, Girouin N, Cheikh AB, Belot A, Rabilloud M, Gelet A, Chapelon JY, Rouvière O.
    BJU Int; 2011 Dec; 108(11):1776-81. PubMed ID: 21711432
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience.
    Blana A, Walter B, Rogenhofer S, Wieland WF.
    Urology; 2004 Feb; 63(2):297-300. PubMed ID: 14972475
    [Abstract] [Full Text] [Related]

  • 17. High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure.
    Blana A, Brown SC, Chaussy C, Conti GN, Eastham JA, Ganzer R, Murat FJ, Pasticier G, Rebillard X, Rewcastle JC, Robertson CN, Thuroff S, Ward JF.
    BJU Int; 2009 Oct; 104(8):1058-62. PubMed ID: 19388986
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.